For research use only. Not for human consumption.
PeptUptidesPEPTUPTIDES
5-Amino 1MQ research vial, front view
50mgNNMT inhibitor (small molecule)

5-Amino 1MQ

A quinolinium small-molecule inhibitor of nicotinamide N-methyltransferase, not a peptide.

Purity
99.2%
Lot
PU-03B8
Format
Lyophilized powder
View COACertificate matched to lot PU-03B8
$75.00

  • Third-party tested
  • Discreet packaging
  • Same-day shipping
  • Encrypted checkout

For research use only. Not for human consumption.

Mechanism of Action

5-Amino-1MQ is a small molecule, not a peptide. It is studied as an inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using S-adenosylmethionine as methyl donor - a reaction that consumes both a NAD+ precursor and a methyl group.

The kinetic mechanism of NNMT was characterised in Biochemistry in 2018, and inhibitor design for the enzyme was reviewed in RSC Medicinal Chemistry in 2021. A 2021 Molecular Metabolism review positions the enzyme at the intersection of cellular metabolism and epigenetic regulation, which is the rationale for targeting it.

Research Findings

The published NNMT literature is dominated by oncology and hepatology: macrophage polarisation, EGFR-TKI resistance, fatty liver disease and cancer metabolism. A 2025 Nature paper reported that NNMT inhibition in cancer-associated fibroblasts restored antitumour immunity in the model studied.

A 2025 Pharmacological Research study examined cardiac function and structure in a heart failure model. Most of this work concerns the enzyme rather than this specific inhibitor, and that distinction matters when designing experiments.

Storage & Reconstitution

Sealed lyophilized vials are stored in the dark. The peptide-formulation literature regards the dry solid as the stable state and the solution as the fragile one: refrigeration at 2-8 degrees C is standard for short holding periods, and minus 20 degrees C or colder for long-term storage. Vials are brought to room temperature before opening so that atmospheric moisture does not condense onto the cold solid. As a small molecule rather than a peptide, this compound is typically prepared in an organic co-solvent; solubility should be confirmed for the intended assay buffer.

For reconstitution, the diluent is added slowly down the inner wall of the vial rather than directly onto the cake, and the vial is swirled rather than shaken - agitation at an air-liquid interface is a well-documented driver of peptide aggregation. The solid should dissolve to a clear, particle-free solution; persistent cloudiness or visible particulate indicates the material should not be used.

Reconstituted solution is held at 2-8 degrees C and protected from light. Freeze-thaw cycling is the single most avoidable cause of loss, so where a solution must be frozen it is aliquoted first into single-use volumes. Working aliquots are labelled with the lot number so that any result can be traced back to the certificate of analysis for that lot.

Handling summary

Physical form
Lyophilized powder, sealed vial
Sealed storage
2-8 C short term / -20 C long term
Reconstituted
2-8 C, protected from light
Diluent
Bacteriostatic water, added down the vial wall
Avoid
Shaking, freeze-thaw cycling, direct light

References

Every entry below links to its PubMed record. Publication is not endorsement: several of these papers report limitations, negative findings or adverse events, and they are listed for that reason.

  1. [1]
  2. [2]
  3. [3]
  4. [4]
  5. [5]
  6. [6]